Iron distribution in cancer cells following doxorubicin exposure using proton and X-ray synchrotron radiation microprobes

• Published in: NUCL INSTRUM METHODS PHYS RES SECT B Vol. 181; no. 1; pp. 480 - 484
• Main Authors: Ortega, R., Devès, G., Bohic, S., Simionovici, A., Ménez, B., Bonnin-Mosbah, M.
• Format: Journal Article Conference Proceeding
• Language: English
• Published: Elsevier B.V 01.07.2001; Elsevier
• Subjects: Cancer; Catalyst activity; Chelation; Doxorubicin; Drug dosage; Instrumentation and Detectors; Iron; Nuclear microprobe; Physics; Synchrotron; Synchrotron radiation; Tissue culture; X ray analysis; Xanes; 61.10.H; 87.64; 78.70.D; Nuclear microprobe; 78.70.E; Xanes; 07.79; Iron; Synchrotron; Doxorubicin; Cancer
• ISSN: 0168-583X; 1872-9584
• DOI: 10.1016/S0168-583X(01)00476-1

Chemical studies have shown that doxorubicin, a well-established anticancer agent, is a powerful iron chelator and the resultant iron–drug complex is an efficient catalyst of the conversion of hydrogen peroxide to the highly reactive hydroxyl radical. However, the intracellular complexation of doxorubicin with iron is still debated. Using nuclear microprobe analysis (NMPA), we previously observed in human ovarian cancer cells exposed to 20 μM iodo-doxorubicin (IDX) that iodine and iron cellular distributions were spatially correlated, suggesting a mechanism of intracellular iron chelation by the anthracycline compound. Because maximal plasma drug concentrations in patients are expected to be around 5 μM, NMPA and X-ray absorption near edge spectroscopy (XANES) experiments for iron speciation analysis were performed on cultured cells exposed to pharmacological doses of 2 μM IDX or doxorubicin.